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1. Introduction 
Intraoperative Floppy Iris Syndrome (IFIS) has received a significant amount of attention 
and subsequent research since it was first reported in 2005 (Bell et al., 2009; Blouin et al., 
2007; Chang & Campbell, 2005; Chang et al., 2007; Oshika et al., 2007; Srinivasan et al., 2007; 
Takmaz & Can, 2007). Current and former uses of alpha-1 adrenergic receptor (α1AR) 
antagonists—most notably tamsulosin—appear to be at the highest risk for this surgical 
complication (Chang & Campbell, 2005). IFIS is characterized by loss of muscle tone in the 
iris, thereby preventing mydriasis and involves a triad of pupil constriction, fluttering and 
billowing of the iris stroma, and propensity for iris prolapse during cataract surgery (Chang 
& Campbell, 2005). While α1AR antagonists are often used for various urological conditions, 
they also block α1AR receptors in the iris dilator muscle and may worsen muscle tone and 
lead to the iris billowing sometimes seen in cataract surgery. Without adequate pupil 
dilation, IFIS reduces visualization of the surgical field, including the cataract itself. This 
impairs removal and can lead to other complications including rupture of the posterior 
capsule, which further increases the risk of other vision-threatening complications of 
cataract surgery (Schwinn & Afshari, 2006).  
2. Use of alpha-1 adrenergic receptor (AR) antagonists 
Since there is a significant association between α1AR antagonist use and IFIS, a brief review 
of the indications of α1AR antagonists is necessary to identify the at-risk population. The 
principal indication is treatment of benign prostatic hyperplasia (BPH). This urological 
disorder shares risk factors with cataract development, with advanced age being the most 
significant (Congdon et al., 2004). If left untreated, BPH increases risk for significant 
complications including acute urinary retention, recurrent urinary tract infections, and 
urinary incontinence (Crawford et al., 2006). In patients with mild BPH as indicated by an 
American Urological Association (AUA) scores of 8 or less, pharmacotherapy may not be 
indicated as lower urinary tract symptoms (LUTS) often improve spontaneously. Identifying 
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suitable candidates for this strategy, often called “watchful waiting,” is critical to reduce 
unnecessary exposure to α1AR therapy and is recommended by the AUA to invariably 
reduce risk for IFIS (American Urological Association [AUA], 2010). Pharmacotherapy for 
BPH is indicated in patients with moderate to severe disease and includes the 5-alpha 
reductase inhibitors (5ARI) and α1AR receptor antagonists. The 5ARI finasteride and 
dutasteride inhibit conversion of testosterone to dihydrotesterone, thereby shrinking the 
prostate; the α1AR antagonists reduce bladder outlet obstruction by relaxing prostatic 
smooth muscle tissue surrounding the urethra. The currently available agents include 
terazosin, doxazosin, alfuzosin, tamsulosin, and silodosin. They have comparable effects in 
symptom reduction (Djavan et al., 2004; Marks et al., 2009). While terazosin and doxazosin 
were originally developed for treatment of hypertension, their use for this indication has 
waned largely due to publication of the ALLHAT trial which demonstrated a higher 
incidence of hospitalization for congestive heart failure (CHF) in the doxazosin arm relative 
to chorthalidone (ALLHAT, 2000). Subsequent “uroselective” agents that target the α1A AR 
have been developed including tamsulosin, and most recently silodosin. (Package insert 
Flomax 2007; Package insert Rapaflo 2008). Alfuzosin’s improved tolerability is largely 
attributable to its extended-release formulation, which prevents peaks in serum 
concentrations (Roehrborn et al., 2000) 
Aside from the robust data demonstrating benefit in men with BPH, these agents have an 
emerging role in other areas of urology including facilitating the passage of urinary caliculi, 
as an adjunctive treatment for chronic prostatitis, following ureteral stent placement, and 
also improving symptoms of overactive bladder in select patients (Anothaisintawee et al., 
2011; Kaplan et al., 2006; Navanimitkul & Lojanapiwat, 2010; Singh et al., 2007). Use of α1AR 
is limited outside the urological arena; however, some patients are undoubtedly still taking 
them for treatment refractory hypertension. Finally, data suggests that prazosin—an agent 
no longer endorsed by the AUA for treatment of BPH due to its unfavorable adverse effect 
and pharmacokinetic profile—has been shown to be effective in reducing nightmares 
secondary to post-traumatic stress disorder (PTSD) (Dierks et al., 2007; Raskind et al., 2003). 
It is imperative that ophthalmologists recognize the various indications for α1AR therapy to 
identify those at risk for IFIS. While men are at higher risk based on their respective use of 
α1AR for treatment of BPH, physicians should recognize that that some women may be 
taking these agents for other indications as well.  
3. Pathophysiology of IFIS 
The α1ARs are G-protein coupled receptors and subdivided into α1AAR, α1BAR, and α1DAR 
subtypes. Stimulation of α1AR elicits contraction of cardiac and most innervated vascular 
smooth muscle throughout the body (Biaggioni & Robertson, 2009). Like the iris dilator 
muscle, the prostate contains a significant volume of smooth muscle rich in ARs. BPH and 
its associated LUTS involve the prostate, urethra, bladder, and spinal cord. The α1A and 
α1DAR predominate in these organs, but α1BAR are also present. As the prostate grows in 
BPH, there is upregulation of α1AR expression, with studies demonstrating that expression 
of α1AARs increases up to 9-fold and α1DARs by 3-fold. This upregulation, especially of 
α1AAR, is thought to be responsible for the disproportionate increase in smooth muscle 
contraction and worsening of LUTS in patients with BPH (Thiyagarajan, 2002). Therefore, 
α1AR antagonists are useful in ameliorating symptoms associated with BPH by decreasing 
prostatic urethral resistance although this blockade may influence iris behavior (Shapiro et 
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al., 1992). Specifically, use of α1AR antagonists for BPH relieves straining and hesitancy, 
improves bladder emptying, and increases the force of the urinary stream.  
Commonly used second-generation α1AR antagonists include doxazosin and terazosin, 
although patient tolerability to these agents is variable, with the most vexing clinical 
problems being orthostatic hypotension and dizziness (McNaughton-Collins & Barry, 2005). 
Frail geriatric patients often suffer from gait problems, and the addition of a medication that 
could increase the potential of a fall is undesirable. The increased α1AAR selectivity of the 
third-generation “uroselective” agents tamsulosin and silodosin is postulated to provide 
additional relief of LUTS in patients with BPH without increasing the rate of serious adverse 
cardiovascular effects due to systemic αAR antagonism. (Cantrell et al., 2008; Cantrell et al., 
2010) 
α1AR antagonists not only therapeutically inhibit prostatic α1AR but may also selectively 
antagonize these receptors in the iris dilator muscle. In the iris, α1AAR mediate iris dilator 
smooth muscle contraction whereas iris arteriolar contraction is mediated via α1BAR. 
Blockade of this muscle’s α1AR is hypothesized to lead to poor muscle tone and the 
subsequent iris billowing sometimes seen in cataract surgery (Schwinn & Afshari, 2006). 
Figure 1 illustrates the clinical dilemma of IFIS and the subsequent potential for surgical 
complications.  
 
 
Adapted or Reprinted with permission from 'Editorials: Floppy Iris Syndrome: Why BPH 
Treatment Can Complicate Cataract Surgery,' June 15, 2009, American Family Physician. Copyright © 
2009 American Academy of Family Physicians. All Rights Reserved 
Fig. 1. Iris damage following cataract surgery in a patient taking tamsulosin 
Although Chang and Campbell first associated IFIS with tamsulosin in 2005, other 
available α1AR antagonists were subsequently linked to IFIS as well (Dhingra et al., 2007; 
Herd, 2007; Package insert Rapaflo, 2008; Settas & Fitt, 2006; Venkatesh et al., 2007). 
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Potentially, the high α1AAR-specific antagonism of tamsulosin made the association easier 
to identify. In rabbits, tamsulosin was more effective than the non-specific α1AR 
antagonist alfuzosin at blocking adrenergic-mediated iris dilator contraction (Palea et al., 
2008). Interestingly, functional studies assessing the affinity of different ARs as measured 
by pKi (negative logarithm of the equilibrium dissociation constant) reflect higher affinity 
of silodosin for α1AAR compared to older agents; when compared to other currently 
available α1AR antagonists, silodosin is 1400 times more specific in terms of α1AAR versus 
α1BAR binding than doxazosin and terazosin and 40 times greater compared to tamsulosin 
(Thiyagarajan, 2002). It remains to be seen if silodosin has a greater likelihood to cause 
IFIS than the other available agents. 
In a rabbit study, Palea et al. suggested an additional unrecognized receptor may be 
involved in contraction of the iris dilator muscle as α1AR blockade with tamsulosin and 
alfuzosin was less prominent in the iris than the prostate (Palea et al., 2008). While α1AAR 
are commonly reported as the predominant subtype in the iris dilator muscle in animal 
studies (Suzuki et al., 2002; Yu & Koss, 2003), Flach pointed out that assuming α1AAR 
predominate in the human iris dilator muscle based off rabbit studies may be misleading 
(Flach, 2009). Nevertheless, human immunohistochemical analysis has shown α1AARs to 
localize to iris arteriolar muscularis and the iris dilator muscle (Panagis et al., 2010). 
4. Risk factors for IFIS 
The most comprehensive assessment of risk factors for IFIS was recently published. This 
meta-analysis included seventeen studies totaling 17,588 eyes (Chatziralli & Sergentanis, 
2010). It assessed current use of α1AR antagonist therapy as well as the effect of co-variates 
hypertension and diabetes. Current tamsulosin use was associated with the highest risk 
among the groups studied. Current use of alfuzosin and terazosin was associated with 
lower risk relative to tamsulosin but remained statistically significant. The pooled analysis 
of doxazosin did not reach statistical significance; however, the authors cautioned that more 
studies are needed to gain statistical power. Of the covariates tested, only current 
hypertension increased risk for IFIS. Despite mixed results in various studies, diabetes did 
not emerge as a significant risk factor for IFIS. The authors concluded that, consistent with 
previous reports, it appears that tamsulosin use is associated with the highest risk of IFIS 
relative to other agents.  
There is limited information regarding doxazosin, prazosin and the most recently approved 
agent silodosin. However, as the latter’s pharmacology most resembles tamsulosin and 
because of its high affinity for the α1AAR, it should be presumed that there is an inherent 
risk with silodosin until data suggests otherwise. A complete list of medications medications 
associated with IFIS is described in Table 1. 
5. Literature review 
IFIS was originally reported in a retrospective study of 511 patients who underwent 
cataract surgery (Chang & Campbell, 2005). Twenty-seven patients (5.3%) totaling 40 
eyes had preoperative exposure to α1AR antagonists. Ten of sixteen (62.5%) patients who 
received tamsulosin prior to surgery developed IFIS. In the remaining eleven patients on 
other α1AR antagonists, there were no documented cases of IFIS. However, the authors 
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reported that all twenty-seven patients had “poor or moderately poor dilation.” A 
complete list of studies assessing incidence of IFIS as well as studies assessing rates of 
surgical complications in patients prescribed α1AR antagonists are described in Table 2 
 
 
Table 1. Medications associated with IFIS 
In a prospective analysis of 900 consecutive cataract surgeries among 741 patients, IFIS was 
observed in sixteen patients (2.2%), fourteen of whom had documented concomitant use of 
tamsulosin (Chang & Campbell, 2005). In the two remaining patients, one had discontinued 
tamsulosin three years prior to surgery, and one had no history of tamsulosin exposure. 
Furthermore, IFIS was reported in both eyes of the five patients taking tamsulosin that 
required bilateral cataract surgery.  
Despite the authors' initial identification of a potentially serious complication of cataract 
surgery, reported limitations of the study include lack of covariate data and the modest 
reported use of α1AR antagonists at 1.9% (Chang & Campbell, 2005; Schwinn & Afshari, 
2006). As stated above, patients with BPH may not always require pharmacologic treatment, 
specifically in patients with mild American Urological Association (AUA) symptom scores 
(AUA, 2010). This may partially explain the relatively low percentage of tamsulosin use in a 
population with a historically high prevalence of BPH.  
In a recent study assessing incidence, IFIS was reported to be 1.6% among 774 patients 
(Takmaz & Can, 2007). IFIS was documented in 14 of 18 patients (77.8%) taking 
tamsulosin, and consistent with the original report by Chang and Campbell, tamsulosin 
use overall was observed in 2.2% of patients. Duration of tamsulosin use—although 
increased among patients diagnosed with IFIS—was not statistically significant relative to 
those without IFIS.  
A recent study directly compared the incidence of IFIS attributable to tamsulosin with an 
active comparator group. (Blouin et al., 2007). In this retrospective study of 64 men totaling 
92 eyes, there was an increased risk of IFIS in patients exposed to tamsulosin (86.4%) when 
compared to alfuzosin (15.4%). The adjusted odds ratio for IFIS in patients taking 
tamsulosin when compared to alfuzosin was 32.15 (95% confidence interval, 2.74-377.41). 
Furthermore, a five-fold increase in surgical complication rates was observed in patients 
diagnosed with IFIS, highlighting its clinical significance.  
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Reference Design Objective Population
Overall 
Prevalence 
or 
Incidence 
of IFIS (%)
Exposure 
to Systemic 
α1AR 
Antagonist 
(%) 
Prevalence or 
Incidence of 
IFIS in 
Tamsulosin-
Treated 
Patients (%) 
Comments 
Chang & 
Campbell, 
2005 
Clinical 
study 1: 
retrospectiv
e chart 
review 
Assess 
incidence 
and possible 
causative 
factors of 
IFIS 
511 
patients; 
706 eyes 
10/511 
patients 
(2.0) 
27/511 
patients 
(5.3) 
10/16 
patients (62.5)
 
Clinical 
study 2: 
prospective 
case series 
741 
patients; 
900 eyes 
16/741 
patients 
(2.2) 
Not 
available 
15/16 
patients (93.8)
 
Chang  
et al., 2007 
Prospective, 
multicenter, 
nonrandomiz
ed 
observational 
series 
Evaluate 
surgical 
outcomes 
and rate of 
complication
s when 
ophthalmolo
gist knew 
patient was 
taking 
tamsulosin 
135 
patients; 
167 eyes 
No IFIS: 
10% of eyes; 
mild: 17% 
of eyes; 
moderate – 
severe: 
73% of 
eyes 
135/135 
patients 
(100) 
150/167 eyes 
(89.8) 
 
Blouin  
et al., 2007 
Retrospectiv
e chart 
review 
Compare 
IFIS risk in 
men taking 
tamsulosin 
vs. alfuzosin
332 
patients; 
461 eyes 
61/461 
eyes (13.2)
64/332 
patients 
(19.3) 
19/22 
patients (86.4)
IFIS in 2/13 
(15.4%) patients 
exposed to 
alfuzosin 
Srinivasan 
et al., 2007 
Retrospectiv
e chart 
review 
Determine 
occurrence of 
IFIS in those 
exposed to 
systemic 
α1AR 
antagonists 
1298 
patients; 
1612 eyes
13/1298 
patients 
(1.0) 
65/1298 
patients 
(5.0) 
10/13 
patients (76.9)
IFIS in 2 patients 
exposed to 
terazosin and 1 
patient exposed to 
doxazosin 
Takmaz & 
Can, 2007 
Prospective, 
nonrandomi
zed 
observation
al study 
Evaluate 
complication 
rates, effect 
of 
intracameral 
adrenaline, 
and 
incidence of 
IFIS in 
patients 
taking 
tamsulosin 
774 
patients; 
858 eyes 
16/858 
eyes (1.9) 
24/858 
eyes (2.8) 
14/18 eyes 
(77.8) 
IFIS in 1 of 4 eyes 
exposed to 
terazosin and 1 of 2 
eyes exposed to 
alfuzosin 
Oshika  
et al., 2007 
Prospective, 
intervention
al case series
Compare 
incidence of 
IFIS with 
topical vs. 
systemic 
α1AR 
antagonists 
1968 
patients; 
2643 eyes
29/2643 
eyes (1.1) 
134/2643 
eyes (5.1) 
25/58 eyes 
(43.1) 
No IFIS in 
bunazosin (topical 
a1AR antagonist 
which is not 
a1AAR-specific) 
group 
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Reference Design Objective Population
Overall 
Prevalence 
or 
Incidence 
of IFIS (%)
Exposure 
to Systemic 
α1AR 
Antagonist 
(%) 
Prevalence or 
Incidence of 
IFIS in 
Tamsulosin-
Treated 
Patients (%) 
Comments 
Amin et al. 
(2008) 
Prospective 
observation
al study 
Assess
incidence of 
IFIS 
associated 
with 
tamsulosin
1267 
patients; 
1462 eyes
Not 
available 
Not 
available 
13/23 eyes 
(56.5) 
 
Keklikci  
et al. (2009) 
Prospective, 
nonrandomi
zed 
observation
al study 
Assess
incidence of 
IFIS 
associated 
with 
tamsulosin 
579 
patients; 
594 eyes 
15/579 
eyes (2.6) 
Not 
available 
12/23 
patients (52.2)
 
Chen  
et al. (2010) 
Retrospectiv
e cohort 
study 
Determine 
incidence of 
IFIS in 
patients 
taking 
tamsulosin, 
effect of  
prophylactic 
measures  
1163 eyes
Not 
available 
Not 
available 
24/81 eyes 
(29.6) 
 
Horvath & 
Vultur 
(2011) 
Prospective, 
nonrandomi
zed 
observation
al study
Report 
incidence, 
etiology and 
management 
of IFIS 
438 
patients; 
439 eyes 
37/439 
eyes (8.4)a
15/439 
eyes (3.4) 
Not available
Incidence of IFIS in 
patients treated 
w/α1AR = 86.7%  
a Includes patients that experienced an IFI-like syndrome 
Table 2. Incidence and prevalence of IFIS in selected studies   
Following the original report suggesting a stronger link between tamsulosin and IFIS 
relative to other α1AR antagonists, subsequent case reports of IFIS have been published in 
men taking alfuzosin, doxazosin, and terazosin (Dhingra et al., 2007; Herd, 2007; Settas & 
Fitt, 2006; Venkatesh et al., 2007). 
Aside from IFIS, α1AR antagonist therapy prior to cataract surgery has been shown to 
predispose patients to complications following cataract surgery (Bell et al., 2009). A nested 
case control study examined health care records of 96,128 Canadian men aged 66 years or 
older who had undergone cataract surgery over a 5 year period. Post-operative 
complications that were examined included retinal detachment, lost lens or lens fragment, 
or endophalmitis. Overall, 3.7% had a history of exposure to tamsulosin, and 7.7% had 
recently taken other alpha blockers. Cases—that is men with a history of complications—
were matched to control patients. The authors identified complications in 280 patients 
(0.3%). These cases were randomly matched to control patients based on age, surgeon, and 
year of procedure. Complications were more common among current users of tamsulosin. 
This risk was not significantly increased with exposure to other α1AR antagonists or to 
previous exposure to tamsulosin or other α1AR antagonists. However, tamsulosin use 
within 14 days of cataract surgery increased the risk for complications.  
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Currently, risk of IFIS has only been associated with systemic use of α1AR antagonists. In a 
study comparing the incidence of IFIS between topical and systemic administration, no 
cases were observed in patients taking bunazosin, a topical, non-selective, α1AR antagonist 
which is not currently available in the United States (Oshika et al., 2007). In the tamsulosin 
comparator group, the incidence of IFIS was 1.1%. Notably, results may have differed had 
the topical agent used also been specific for the α1AAR subtype. 
In response to multiple reports of an increased risk of IFIS, the package labeling of 
tamsulosin and other α1AR antagonists has been updated to reflect this potential risk. The 
labeling further acknowledges that benefits of stopping an α1AR antagonist prior to cataract 
surgery remains unknown (Package insert Flomax, 2007). 
The 5ARI finasteride and the extract of saw palmetto (Serona repens) a type of palm plant 
utilized largely as alternative medicine for treatment of BPH have been linked to IFIS (Issa & 
Dagres, 2007; Yeu & Grostern, 2007). The patients in the aforementioned cases were 
specifically stated to not have received α1AR antagonists prior to cataract surgery; however, 
the possibility exists that the patients may have received an unrecognized α1AR antagonist 
either currently or in the past. No mechanism for how these agents may cause IFIS has been 
postulated, and the effect of how 5ARIs interact with the iris has not been studied. While 
confounders common to patients taking either 5ARIs or α1AR antagonists such as increased 
age or male gender cannot be ruled out, certainly the strongest evidence of a link between 
medication and IFIS is with α1AR antagonists and not 5ARIs.  
Aside from α1AR antagonists, IFIS has been associated with other medications as well. 
Lending credence to the theory that α1AR antagonism is heavily responsible for IFIS, the 
antipsychotics chlorpromazine and risperidone, both mild α1AR antagonists, have been 
linked to IFIS in patients not previously haven received conventional α1-AR antagonists 
(Ford et al., 2011; Unal et al., 2007).  Labetalol, a dual α1- and β-AR antagonist, has also been 
associated with IFIS (Calotti & Steen, 2007). 
One case of acetylcholinesterase-inhibitor-associated IFIS with donepezil has been reported. 
The authors hypothesized that through enhancement of cholinergic activity on the pupil 
sphincter, the pharmacological effect of the preoperative dilating drops was overcome 
(Papadopoulos & Bachariou, 2007). The patient reportedly had never received an α1AR 
antagonist. However, a complete medication list was not documented in the case, and 
receipt of other α1AR antagonists cannot be ruled out. 
6. Pre-operative evaluation  
The relationship of α1AR antagonists to IFIS has changed the preoperative process for  
cataract surgeons. The pre-operative evaluation is particularly difficult as there is currently 
no reliable way to predict which patients will demonstrate IFIS. Furthermore as IFIS can 
present unilaterally the absence in one eye does not preclude the other eye from 
demonstrating features of IFIS in a subsequent surgery (Issa et al., 2008). During the pre 
operative visit, there are a number of questions and observations which may highlight for 
the surgeon any patients at potential risk for IFIS.  
Most importantly is to ask all patients about current or former use of α1AR antagonists. 
Simply reviewing the current medication list is not sufficient. Many patients are unable to 
recall specific medication names or classes they are currently taking, much less a medication 
they took previously and since discontinued. Because of this, often times asking a patient or 
an accompanying family member if they have ever been treated for an enlarged prostate or 
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for difficulty emptying their bladder will help elicit a more accurate history. If a patient does 
have a history of α1AR antagonists it is also important to counsel them on the associated 
increased risk of IFIS and subsequent risk of complications postoperatively.  
The most reliable preoperative predictive feature of IFIS in a patient with a history of α1AR 
antagonists is poor pupillary dilation (Oetting, 2009). This can and should be noted during 
the office pre-operative cataract surgery evaluation, and not just on the day of surgery. 
When the pupil does not dilate well, the surgeon should be wary of IFIS during surgery. 
Although poor dilation can also be a harbinger of other intra ocular conditions such as 
pseudoexfoliation and trauma,  recognition will help the surgeon prepare for and adapt 
intra operative management strategies for all possible complications (Altan-Yaycioglu. et al., 
2007). 
7. Conclusion 
Recognizing patients at risk for IFIS is paramount to management. Without adequate 
preparation and management IFIS and subsequent postoperative complications are possible. 
A detailed pre-operative evaluation including recognizing those at risk for IFIS will ensure 
the best outcome.  
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